Features

18 Dec 03

Transplantation immunotherapy commonly involves the use of azathioprine often combined with low doses of cyclosporine. Increased susceptibility to infection and severe toxicity represent serious adverse effects and a newer molecular target being investigated for the prevention of transplant rejection is Janus tyrosine kinase 3 (Jak3). Jak3 is this months "Target of the Month" from LeadDiscovery's and here they describe Pfizer's efforts to optimize inhibitors of this kinase
LeadDiscovery

15 Dec 03

This comprehensive one-day training offers MSLs, their managers and those interested in a better understanding of the profession an overview of what the job entails, best practices and realistic ways to incorporate them into your own job. The training will focus on the components of a successful career as a MSL, as opposed to educating on individual therapeutic types.
Jennifer McGinnis

19 Nov 03

The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts
LeadDiscovery

04 Nov 03

It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition. This comprehensive report evaluates breaking drug discovery targets and therapeutic candidates for the treatment of this disease
LeadDiscovery

21 Oct 03

Despite the media publicity that meningitis attracts when there is an outbreak, it remains one of the most serious infectious diseases facing the world - affecting populations in affluent and poorer countries alike.
Dr Faiz Kermani

15 Oct 03

Worldwide, 95 million people suffer from wounds that result in tissue loss. Wound healing problems extend hospital stays, especially in the elderly, resulting in an additional $1.5 billion in healthcare costs in the US alone. LeadDiscovery’s current target of the month focuses on connexin43, blocking of which produces a dramatic improvement in wound healing. In this feature we also describe how antisense technology has been applied to develop a licensing opportunity in this area
LeadDiscovery

01 Oct 03

"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
LeadDiscovery

23 Sep 03

"Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity" represents a cutting edge analysis of why and how ghrelin should be targeted for the identification of new therapies for obesity
LeadDiscovery

15 Aug 03

Some of the world’s leading drugs, such as Bristol-Myers Squibb’s pravastatin for high cholesterol, TAP’s lansoprazole and Daiichi’s levofloxacin were discovered in Japanese laboratories. With this history of important drug research there is keen interest in biotechnology.
Dr Faiz Kermani

05 Aug 03

Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
LeadDiscovery

29 Jul 03

Faced with rising costs, shortened product lifecycles and an increasing reliance on blockbuster drugs, pharmaceutical companies are turning towards innovative marketing campaigns and new channels to reach an increasingly demanding consumer audience. Offering particular potential, campaign management solutions are being introduced to establish profitable interactions with large numbers of consumers across multiple channels.
Michael Randle

07 Jul 03

The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscovery’s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
LeadDiscovey

03 Jun 03

To mark the American Society of Clinical Oncology's 2003 conference, LeadDiscovery has launched The Oncology Collection. The Oncology Collection groups all of LeadDiscovery's oncology services in one
LeadDiscovery

30 May 03

This edition of
LeadDiscovery

20 May 03

Canadian researchers have successfully treated animals with experimental pulmonary hypertension with a vector expressing the Kv1.5 potassium channel gene
LeadDiscovery